Tıp Fakültesi Öğrencilerinin Metabolik Sendrom Farkındalık Düzeylerinin İncelenmesi

Amaç: Sunulan çalışmada bir halk sağlığı sorunu olarak tanımlanan ve etkilenen bireyde abdominal obezite, hiperglisemi, hipertansiyon, insülin direnci ve dislipidemi ile birliktelik gösteren metabolik sendrom konusunda, gelecekte bu hastalarla doğrudan etkileşimde bulunma potansiyeli taşıyan tıp fakültesi öğrencilerinin farkındalık düzeylerinin incelenmesi amaçlandı. Bu sayede klinik öncesi ve sonrası dönemler arasındaki farkındalık düzeylerinin tespiti hedeflendi. Yöntem: Bu amaçla görece yeni bir risk skoru anketi olan JAMRISC, klinik öncesi ve sonrası olarak gruplandırılan tıp fakültesi öğrencilerine uygulandı. Çalışmaya toplam olarak yaşları 17-29 arasında değişkenlik gösteren (kadın:68 (%41,7), erkek:95(%58,3)) 163 tıp fakültesi lisans öğrencisi dahil edilmiştir ve bu öğrencilerin tümüyle anket gerçekleştirilmiştir. Bulgular: Çalışmanın sonuçlarına göre pre-klinik ve klinik öğrencilerinin demografik verilerine göre yaş ve cinsiyet bakımından istatistiksel olarak anlamlı bir farklılık görülmüştür (sırasıyla; p

THE RELATIONSHIP BETWEEN MALIGNANCY AND PRIMARY SJOGREN'S SYNDROME; SINGLE CENTER RESULTS

Objective: In this study, we aimed to present malignancy data in patients who were followed up in our outpatient clinic with a diagnosis of primary Sjogren’s syndrome (pSS).Methods: Data of 151 patients diagnosed with pSS between 2004-2019 were retrospectively reviewed and clinical, demographic characteristics of 14 patients diagnosed with malignancy were examined. Standardized incidence ratios (SIRs) were calculated.Results: All 14 patients with malignancy were female, their mean age was 55.9±12 years, and the disease duration was 10.5±5.3 years. Malignancy was detected in 9% of the patients who were followed up with the diagnosis of pSS. One patient was diagnosed with cervix cancer (CA), four patients with breast CA, three patients with thyroid papillary CA, one patient with MALT (mucosa-associated lymphoid tissue) lymphoma, one patient with diffuse large B-cell lymphoma (DLBCL), one patient with mycosis fungoides, one patient with vulvar epithelial carcinoma, and two patients with lung CA. Patients with malignancy and those without were compared in terms of clinical and laboratory findings. There was a significant difference between the presence of LAP and ILD and EULAR primary Sjogren's syndrome disease activity ındex (ESSDAI) activity scores of two groups.Conclusion: In our study, an increased risk was observed for both hematological [SIR27.27 (95% CI 5.6-79.7)] and solid malignancies [SIR 7.75 (95% CI 3.9-13.9)] in Sjogren's Syndrom.

___

  • 1. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: Definitions and controversies. BMC Med. 2011;9(Appendix 1):1-13. doi:10.1186/1741-7015-9-48
  • 2. Bener A, Zirie M, Musallam M, Khader YS, Al-Hamaq AOAA. Prevalence of metabolic syndrome according to adult treatment panel III and international diabetes federation criteria: A population-based study. Metab Syndr Relat Disord. 2009;7(3):221-230. doi:10.1089/met.2008.0077
  • 3. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes. 2004;53(8):2087-2094. doi:10.2337/diabetes.53.8.2087
  • 4. Christian Flemming GM, Bussler S, Körner A, Kiess W. Definition and early diagnosis of metabolic syndrome in children. J Pediatr Endocrinol Metab. 2020;33(7):821-833. doi:10.1515/jpem-2019-0552
  • 5. Pucci G, Alcidi R, Tap L, Battista F, Mattace-Raso F, Schillaci G. Sex- and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: A review of the literature. Pharmacol Res. 2017;120:34-42. doi:10.1016/j.phrs.2017.03.008
  • 6. Stanaway JD, Afshin A, Gakidou E, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Stu. Lancet. 2018;392(10159):1923-1994. doi:10.1016/S0140-6736(18)32225-6
  • 7. Weihe P, Weihrauch-Blüher S. Metabolic Syndrome in Children and Adolescents: Diagnostic Criteria, Therapeutic Options and Perspectives. Curr Obes Rep. 2019;8(4):472-479. doi:10.1007/s13679-019-00357-x
  • 8. Yahia N, Brown C, Rapley M, Chung M. Assessment of college students’ awareness and knowledge about conditions relevant to metabolic syndrome. Diabetol Metab Syndr. 2014;6(1):1-15. doi:10.1186/1758-5996-6-111
  • 9. Makrilakis K, Liatis S, Grammatikou S, et al. Validation du questionnaire finlandais calculant un score de risque de diabète (FINDRISC) pour le dépistage du diabète de type 2, des anomalies de la glycorégulation et du syndrome métabolique en Grèce. Diabetes Metab. 2011;37(2):144-151. doi:10.1016/j.diabet.2010.09.006
  • 10. Saaristo T, Peltonen M, Lindström J, et al. Cross-sectional evaluation of the Finnish Diabetes Risk Score: A tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. Diabetes Vasc Dis Res. 2005;2(2):67-72. doi:10.3132/dvdr.2005.011
  • 11. Janghorbani M, Adineh H, Amini M. Evaluation of the Finnish Diabetes Risk Score (FINDRISC) as a screening tool for the metabolic syndrome. Rev Diabet Stud. 2013;10(4):283-292. doi:10.1900/RDS.2013.10.283
  • 12. Janghorbani M, Adineh H, Amini M. Finnish Diabetes Risk Score to predict type 2 diabetes in the Isfahan diabetes prevention study. Diabetes Res Clin Pract. 2013;102(3):202-209. doi:10.1016/j.diabres.2013.10.018
  • 13. Salinero-Fort MA, Burgos-Lunar C, Lahoz C, et al. Performance of the finnish diabetes risk score and a simplified finnish diabetes risk score in a community-based, cross-sectional programme for screening of undiagnosed type 2 diabetes mellitus and dysglycaemia in madrid, Spain: The SPREDIA-2 study. PLoS One. 2016;11(7):1-17. doi:10.1371/journal.pone.0158489
  • 14. Tan C, Sasagawa Y, Kamo K ichi, et al. Evaluation of the Japanese Metabolic Syndrome Risk Score (JAMRISC): a newly developed questionnaire used as a screening tool for diagnosing metabolic syndrome and insulin resistance in Japan. Environ Health Prev Med. 2016;21(6):470-479. doi:10.1007/s12199-016-0568-5
  • 15. Havakuk O, Perl ML, Praisler O, et al. The awareness to metabolic syndrome among hospital health providers. Diabetes Metab Syndr Clin Res Rev. 2017;11(3):193-197. doi:10.1016/j.dsx.2016.09.005
Acta Medica Nicomedia-Cover
  • Yayın Aralığı: Yılda 3 Sayı
  • Başlangıç: 2020
  • Yayıncı: KOCAELİ ÜNİVERSİTESİKÜTÜPHANE VE DÜKÜMANTASYON DAİ B